Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| PACB | PRESS-RELEASE | neutral | 4/10 | PacBio announced a collaboration with TychoBio, an AI drug discovery company, to generate full-length RNA data using Pac | Oct 6, 2026 |
| NEO | 8-K | mixed | 5/10 | NeoGenomics announced a planned CEO succession: President/COO Warren Stone will become CEO effective Jan 4, 2027, while | Oct 5, 2026 |
| TWST | CLUSTER | bearish | 5/10 | Two insiders at Twist Bioscience sold a combined $2.08M in open-market sales on the same day, including the Chief Accoun | Oct 5, 2026 |
| NTLA | PRESS-RELEASE | neutral | 2/10 | Intellia Therapeutics granted inducement stock awards to eight new employees under its 2024 Inducement Plan. This is a r | Oct 2, 2026 |
| FATE | PRESS-RELEASE | neutral | 2/10 | Fate Therapeutics announced management participation in Q4 2026 investor conferences. No financial results or material b | Oct 1, 2026 |
| ILMN | COURT-RULING | bullish | 6/10 | The federal securities class action against Illumina (ILMN) was dismissed in its entirety by the Southern District of Ca | Sep 29, 2026 |
| FATE | 8-K | bullish | 5/10 | Fate Therapeutics received a $15 million CLIN2 grant from the California Institute for Regenerative Medicine (CIRM) to s | Sep 28, 2026 |
| TWST | CLUSTER | neutral | 3/10 | Three TWST insiders, including CEO Emily Leproust, sold a total of ~$273K in open-market sales over a 7-day window. The | Sep 25, 2026 |
| CRSP | CLUSTER | bearish | 5/10 | Two CRISPR Therapeutics insiders—Director Ali Behbahani and General Counsel James Kasinger—sold a combined $1.41M in ope | Sep 24, 2026 |
| TXG | CLUSTER | neutral | 3/10 | Two insiders at 10x Genomics, including CEO Serge Saxonov, sold a combined $208K in open-market sales on September 22, 2 | Sep 24, 2026 |
| TWST | CLUSTER | bearish | 5/10 | CEO Emily Leproust executed a massive derivative exercise and open-market sale of ~$55M in TWST stock on September 17, 2 | Sep 22, 2026 |
| TXG | 144 | neutral | 2/10 | Shehnaaz Suliman, an affiliate of 10x Genomics, filed a Form 144 notice of intent to sell 5,723 shares of Class A Common | Sep 22, 2026 |
| RXRX | 8-K | mixed | 5/10 | Recursion Pharmaceuticals amended its Master Agreement with Tempus AI, extending the term from five to six years and eli | Sep 21, 2026 |
| DNA | 144 | neutral | 2/10 | Director Christian O. Henry filed a Form 144 notice to sell 5,000 Class A shares (~$35,406 at ~$7.08/sh), representing a | Sep 15, 2026 |
| BNGO | 8-K | bullish | 6/10 | Bionano Genomics presented an investor deck at the H.C. Wainwright conference, highlighting Q2 2026 revenue of $8.2M (ab | Sep 14, 2026 |
| BNGO | PRESS-RELEASE | bullish | 5/10 | Bionano Genomics highlighted three new peer-reviewed publications demonstrating that its optical genome mapping (OGM) te | Sep 14, 2026 |
| TXG | CLUSTER | neutral | 3/10 | Two TXG insiders, including CFO Adam Taich and Director John Stuelpnagel, sold a combined $502K in open-market sales ove | Sep 11, 2026 |
| RXRX | CLUSTER | neutral | 2/10 | CEO Najat Khan and Director Blake Borgeson sold a combined $179K in open-market RXRX shares over a one-week window. The | Sep 10, 2026 |
| TWST | CLUSTER | neutral | 2/10 | Four Twist Bioscience insiders, including CEO Emily Leproust and CAO Robert Werner, sold a total of $473K in open-market | Sep 10, 2026 |
| NTLA | 8-K | bullish | 7/10 | Intellia Therapeutics announced FDA acceptance of its Biologics License Application (BLA) for lonvoguran ziclumeran (lon | Sep 9, 2026 |
| EDIT | EFFECT | neutral | 4/10 | Editas Medicine's S-3 shelf registration (File No. 333-298665) became effective on September 8, 2026. This allows the co | Sep 9, 2026 |
| TXG | 144 | bearish | 4/10 | Director John R. Stuelpnagel filed a Form 144 notice of intent to sell 20,000 shares of Class A common stock, with an es | Sep 3, 2026 |
| TXG | CLUSTER | neutral | 4/10 | A cluster of insider selling at 10x Genomics (TXG) over the past week saw the CEO, CFO, and a director collectively sell | Aug 28, 2026 |
| CRSP | PRESS-RELEASE | bullish | 7/10 | CRISPR Therapeutics presented one-year durability data from its Phase 1a trial of CTX310, an in vivo CRISPR/Cas9 gene ed | Aug 28, 2026 |
| TWST | CLUSTER | neutral | 4/10 | A cluster of insider selling at Twist Bioscience, led by CEO Emily Leproust selling ~$6.3M in open-market transactions o | Aug 28, 2026 |
| ILMN | CLUSTER | neutral | 3/10 | Director Keith Meister sold ~$21.1M of ILMN stock over a 5-day window (Aug 21-27), with the bulk at ~$225-231. SVP Wedel | Aug 27, 2026 |
| TXG | CLUSTER | neutral | 3/10 | CEO Serge Saxonov and CFO Adam Taich sold a combined ~$2.25M in open-market sales on August 24, 2026, at ~$63/share. Thi | Aug 26, 2026 |
| TWST | CLUSTER | neutral | 4/10 | A cluster of insider sales at Twist Bioscience, totaling ~$2.50M over a week, with the CEO, CFO, COO, and other senior e | Aug 26, 2026 |
| TWST | CLUSTER | neutral | 4/10 | Four Twist Bioscience insiders, including CEO Emily Leproust and President/COO Patrick Finn, sold a total of $8.48M in s | Aug 22, 2026 |
| ILMN | CLUSTER | bearish | 4/10 | Director Keith Meister sold ~$4.0M in shares on Aug 19, and SVP Jakob Wedel Christensen sold $198K on Aug 18, totaling $ | Aug 21, 2026 |